

January 16, 2017

News Release

Contact: Paula Darte
Paula.Darte@UHhospitals.org
216.870.6323

**Department of Marketing and
Communications**
11100 Euclid Avenue
Cleveland, OH 44106

**Harrington Discovery Institute at University Hospitals announces
2017 grant funding to 11 physician-scientists**
Scholars are affiliated with 11 premiere universities

Cleveland, Ohio – [The Harrington Discovery Institute](#) at University Hospitals in Cleveland, Ohio, has announced the 2017 recipients of Harrington Scholar-Innovator Awards. The awards support breakthrough discoveries of physician-scientists whose research shows promise to advance the standard of care.

The Harrington Discovery Institute – part of The Harrington Project for Discovery & Development – fulfills an unmet need in academic medicine: to advance early breakthroughs into the clinical realm. Its focus on physician-scientist innovators from across the country and the UK creates opportunity to transform the best innovation regardless of institution affiliation.

In addition to financial support awarded to the winners, the Institute provides direction from leaders in the pharmaceutical industry who are charged with overseeing therapeutic development of Scholar programs. While working with the Institute, physician-scientists (and their institutions) retain the intellectual property for their work.

“Our scholars tell us that the guidance they receive from members of the Harrington Innovation Support Center is absolutely the most valuable part of their time with us—of even greater value than the money,” said [Jonathan Stampler, MD](#), President of the Harrington Discovery Institute. “Research institutions and non-profit endeavors do not typically provide strong pharmaceutical capability. Technology languishes for lack of know-how. We believe that if we can marry the best science with the best practices, we should be able to more effectively advance discovery.”

The selected scholars have access to several rounds of capital (up to a total of \$700,000) through their affiliation with the Harrington Discovery Institute to support the transition of their work into the private sector. Scholars are then free to approach investors of their choice to underwrite the commercialization of their work or they can have facilitated access to BioMotiv, the mission-aligned development company that also is part of The Harrington Project. However, there are no obligations on either side.

The 2017 Harrington Scholar-Innovator grant recipients are:

Paul Bollyky, MD, PhD – Stanford University – *A novel drug for Type I Diabetes*

Ambrose Cheung, MD – Geisel School of Medicine at Dartmouth – *A novel treatment against MRSA and other Gram+ bacterial infections*

Giulio Draetta, MD, PhD – The University of Texas MD Anderson Cancer Center – *A new therapy and first in-human trials for pancreatic cancer*

Seth Field, MD, PhD – University of California San Diego – *A novel pathway causing cancer*

Todd Gould, MD – University of Maryland – *A new medicine for depression*

John Letterio, MD – Case Western Reserve University/University Hospitals – *A promising drug for Alzheimer's disease, stroke and cancer*

David Lombard, MD, PhD – University of Michigan – *A new strategy in melanoma therapy*

Daruka Mahadevan, MD, PhD – University of Arizona – *A novel class of cancer drugs and radiation sensitizers*

Deepak Nijhawan, MD, PhD – University of Texas Southwestern Medical Center – *A first-in-class immunotherapy for cancer*

Stuart Orkin, MD – Harvard University – *A novel treatment for sickle cell disease*

Daniel Ory, MD – Washington University – *A breakthrough treatment for Niemann-Pick C disease, a rare neurological disease*

###

Harrington Discovery Institute

The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation's most inventive physician-scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a \$50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a 'Better World'.

The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a \$300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.

For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.

University Hospitals

Founded in 1866, University Hospitals serves the needs of over 1 million patients per year through an integrated network of 18 hospitals, more than 40 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio. The system's flagship academic medical center, University Hospitals Cleveland Medical Center, located on a 35-acre campus in Cleveland's University Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonalld Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the

most prestigious clinical and research programs in the nation, including cancer, pediatrics, women's health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, dermatology, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including "America's Best Hospitals" from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. UH is the second largest employer in northern Ohio with 26,000 employees. For more information, go to UHhospitals.org.

January 12, 2017

News Release

Harrington Discovery Institute Announces 2016 Partnership Scholars

Cleveland, Ohio – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – has announced its 2016 partnership Scholars selected in collaboration with Alzheimer’s Drug Discovery Foundation (ADDF), and Foundation Fighting Blindness and University of Oxford.

Harrington Discovery Institute collaborations are based on a shared mission to advance discoveries into new medicines that will improve human health, as well as, enhance each organization's ability to play a significant role in setting the scientific and innovation agenda in leading-edge research. These awards offer selected winners funding and expert pharmaceutical guidance to move their discoveries forward and ensure the most promising enter the clinic. Please join us in congratulating our newest scholars.

The 2016 ADDF-Harrington Scholars are:

- Travis Dunckley, PhD, Arizona State University, whose work focuses on using DYRK1A inhibitors to prevent cognitive impairment and Alzheimer’s pathology
- Sung Ok Yoon, PhD, The Ohio State University, whose work focuses on using novel inhibitors of a stress-activated kinase for the treatment of Alzheimer’s disease

The 2016 Gund-Harrington Scholar is:

- David M. Gamm, MD, PhD, University of Wisconsin-Madison, whose work focuses on restoring sight through the use of human pluripotent stem cells in individuals suffering from retinal degenerative disease

The 2016 Oxford-Harrington Scholar is:

- Valentine M. Macaulay, MD, PhD, whose work focuses on disrupting receptor internalization and nuclear translocation as a novel therapy for cancer

“The Cleveland-based Harrington Discovery Institute currently supports promising discoveries in North America and the U.K.,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute. “Our collaborations with disease foundations and like-minded research institutions allow us to better address underserved areas of medicine and to bring forth new medicines where treatments remain elusive.”

“We at the Foundation Fighting Blindness continue to applaud Ron Harrington’s support for accelerating promising research from the bench to clinical studies,” said Gordon

Gund, chairman and co-founder of the Foundation Fighting Blindness. “The Harrington Discovery Institute offers highly pragmatic support to our researchers, based in hundreds of years of collective experience from an impressive cadre of pharmaceutical

R&D executives. Together we are dedicated to helping millions defeat diseases that limit the ability to experience the gift of sight.”

In addition to funding, award recipients receive committed drug development and project management support through the [Harrington Discovery Institute's Innovation Support Center](#) for the duration of the term of the award. This includes consulting and management services from experienced pharmaceutical development professionals, as well as regulatory, intellectual property and business development assistance.

“I am delighted that Professor Macaulay has been selected as the next Oxford-Harrington Scholar,” said Professor Sir John Bell, Regius Professor of Medicine, University of Oxford. “This program will support her novel approach around hormone receptors, which shows promise in treating cancers that touch millions of lives around the world.”

Harrington Scholars have facilitated access to BioMotiv – part of The Harrington Project for Discovery & Development – a for-profit commercialization company that is aligned with the Harrington Discovery Institute in mission and structure. BioMotiv was created to further advance discoveries by academic researchers in areas of unmet need.

“Our collaboration with the Harrington Discovery Institute is proving fruitful in aggregating effort around Alzheimer’s disease R&D,” said Howard Fillit, MD, Founding Executive Director and Chief Science Officer at the ADDF. “Our joint goals are to broaden the portfolio of drug targets in the pipeline and accelerate their development. We recognize the value of The Harrington Project model, and see this important collaboration as a way to advance ADDF’s work, which offers hope to people globally who currently are touched by Alzheimer’s disease and to those who fear it in their future.”

#

Contact information:

For Harrington Discovery Institute
Paula Darte
Director of Media and Public Relations
University Hospitals, Cleveland, Ohio
216-870-6323
Paula.Darte@UHhospitals.org

For Foundation Fighting Blindness
Rhea K. Farberman
Senior Director of Communications and Marketing
410-423-0635
RFarberman@fightblindness.org

For University of Oxford
Liam Murphy
liam.murphy@admin.ox.ac.uk

For Alzheimer's Drug Discovery Foundation
Krishna Knabe
Director of Communications
212-907-7997
kknabe@alzdiscovery.org

Foundation Fighting Blindness has a broad network and deep domain expertise in inherited retinal diseases, a set of programs for funding discoveries and advancing them toward clinical studies, and a robust pipeline of funded projects that represent new therapeutic opportunities. The foundation is funding startup companies and for-profit initiatives through its establishment of the Clinical Research Institute (the CRI), a not-for-profit subsidiary, which can partner to provide substantial later-stage funding for high-potential projects. The Foundation Fighting Blindness is supporting several clinical trials, and many additional gene and stem cell-based human studies could begin in the next several years. For more information, please visit fightblindness.org.

Oxford University's Medical Sciences Division is one of the largest biomedical research centers in Europe, with more than 2,500 people involved in research and more than 2,800 students. The university is rated the best in the world for medicine, and it is home to the U.K.'s top-ranked medical school. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the U.K. and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and health care delivery. A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies that examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions. For more information, please visit medsci.ox.ac.uk.

Alzheimer's Drug Discovery Foundation

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF follows a venture philanthropy model, funding research in academia and the biotechnology industry. And it's the only such charity solely dedicated to funding the discovery and development of drugs for Alzheimer's. Through the support of its donors, the ADDF has awarded more than \$70 million to fund over 450 Alzheimer's drug discovery programs and clinical trials in 18 countries. To learn more, visit alzdiscovery.org.

Harrington Discovery Institute

The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation's most inventive physician-scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a \$50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a 'Better World'.

The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a \$300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery in to pharma pipelines.

For more information about The Harrington Project and Harrington Discovery Institute, visit: HarringtonDiscovery.org.